1.
|
Phase: Phase III, Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 3 to 21 Sponsor: NCI Protocol IDs: NCI-2011-02616, ACNS0822, CDR0000688443, U10CA098543, COG-ACNS0822, NCT01236560
|
|
2.
|
Phase: Phase II, Phase I Type: Treatment Status: Active Age: 2 to 32 Sponsor: Pharmaceutical / Industry Protocol IDs: CNS 0201, NCT00179907
|
|
3.
|
Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 1 to 21 Sponsor: NCI, Other Protocol IDs: CDR0000647587, COG-ADVL0912, ADVL0912, NCT00939770
|
|
4.
|
Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 0 to 21 Sponsor: Other Protocol IDs: Poly ICLC, NCT01188096
|
|
5.
|
Phase: Phase I Type: Treatment Status: Active Age: 21 and under Sponsor: Other Protocol IDs: RADBEV, NCT00756340
|
|
6.
|
Phase: Phase I Type: Treatment Status: Active Age: 18 months to 23 years Sponsor: Other Protocol IDs: ACH-CNS-001, NCT00876993
|
|
7.
|
Phase: No phase specified Type: Treatment Status: Active Age: 3 to 30 Sponsor: Other Protocol IDs: HGG, NCT00890786
|